ROCKVILLE, Md., May 21, 2014 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), a specialty pharmaceutical company, today announced that the Company's management will provide a business update and will be hosting investor meetings during the Jefferies Healthcare Conference.
Date: Wednesday, June 4
Presentation Time: 11:00 am ET
Place: Grand Hyatt Hotel, NYC
Investors interested in arranging a meeting during this conference should contact via email Isabel Zakoscielny at firstname.lastname@example.org.
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system, or CNS, diseases. The Company has two marketed products for epilepsy, Oxtellar XR® (extended-release oxcarbazepine) and Trokendi XR™ (extended-release topiramate). The Company is also developing several product candidates in psychiatry to address large market opportunities in ADHD, including ADHD patients with impulsive aggression. These product candidates include SPN-810 for impulsive aggression in ADHD and SPN-812 for ADHD.
CONTACT: Jack A. Khattar, President and CEO Gregory S. Patrick, Vice President and CFO Supernus Pharmaceuticals, Inc. 301-838-2591 or Investor Contact: Cockrell Group 877-889-1972 email@example.com cockrellgroup.com
Source:Supernus Pharmaceuticals, Inc.